Medicine and Dentistry
Diseases
100%
Breast Cancer
70%
Embryonal Rhabdomyosarcoma
64%
Rhabdomyosarcoma
64%
Germinoma
64%
Supportive Care
56%
Overall Survival
49%
Tumor
47%
Quality of Life
45%
Testis Cancer
40%
Recurrent Disease
37%
Metastatic Carcinoma
34%
Cancer Treatment
32%
Paclitaxel
32%
Intracranial Tumor
32%
Ifosfamide
32%
Biliary Tract Cancer
32%
Programmed Death-Ligand 1
32%
Cisplatin
32%
Diffuse Large B-Cell Lymphoma
32%
Glioblastoma
32%
Endometrium
32%
Gut Microbiome
32%
Liver Graft
32%
Pleura Mesothelioma
32%
Clinical Trial
32%
Cholangiocarcinoma
32%
Neoadjuvant Therapy
32%
Urinary Tract Cancer
32%
Fumaric Acid
32%
Gastrointestinal Stromal Tumor
32%
Cancer Cell
32%
Trastuzumab
32%
Survivorship in Cancer Care
32%
Pertuzumab
32%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
32%
Clear Cell Renal Cell Carcinoma
32%
Fibroblast Growth Factor Receptor
32%
Adjuvant Therapy
32%
Progression Free Survival
31%
Ganglioglioma
29%
Malignant Neoplasm
29%
Survival Rate
28%
Immunotherapy
28%
Germ Cell
27%
Targeted Therapy
24%
Tyrosine-Kinase Inhibitor
24%
Cancer
24%
Somatics
22%
Gut
21%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
79%
Diseases
67%
Germ Cell Tumor
64%
Glioblastoma
64%
Chemotherapy
46%
Biological Marker
46%
Malignant Neoplasm
42%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
42%
Clinical Trial
39%
Breast Cancer
38%
Monotherapy
38%
Survival Rate
34%
Paclitaxel
32%
Ifosfamide
32%
Biliary Tract Cancer
32%
Cisplatin
32%
Testis Cancer
32%
Gastrointestinal Stromal Tumor
32%
Bevacizumab
32%
Taxane
32%
Phosphatidylinositol 3 Kinase Inhibitor
32%
Pertuzumab
32%
Trastuzumab
32%
Phosphatidylinositol 3 Kinase
32%
Progression Free Survival
26%
Immunotherapy
24%
Monoclonal Antibody
20%
Protein Tyrosine Kinase Inhibitor
20%
Solid Malignant Neoplasm
18%
Temozolomide
16%
Recurrent Disease
14%
Epidermal Growth Factor Receptor 2
12%
Gamma Urogastrone
12%
Sunitinib
12%
Disease Free Survival
12%
Combination Therapy
11%
Disease Exacerbation
10%
Endocrine Therapy
10%
Carcinogenesis
10%
Estrogen Receptor Positive Breast Cancer
10%
Estrogen Receptor
10%
Therapy Resistance
10%
Neoplasm
8%
Clinical Research
8%
Lomustine
8%
Antiangiogenic Therapy
8%
Phase III Trials
8%
Connective Tissue Cancer
8%
Tolerability
6%
Glycoprotein
6%